NCT02797795View on ClinicalTrials.gov

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers

PHASE1UnknownINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Advanced CancerSolid Tumors
Interventions
DRUG

NEV801

Dose Escalation

Trial Locations (2)

37203

RECRUITING

Research Facility, Nashville

02215

ACTIVE_NOT_RECRUITING

Research Facility, Boston

Sponsors
All Listed Sponsors
lead

Neovia Oncology Ltd.

INDUSTRY